Neurofix’s NFX88 is at the end of its Phase 2A clinical trial and expects to report results in Q4 2021

Neurofix Pharma is a biopharmaceutical company that specializes in developing innovative drugs for the treatment of Central Nervous System pathologies. Its drug, NFX88, of which the company is a world pioneer, hopes to treat neuropathic pain in patients with spinal cord injury, a condition that affects 25% of the world’s population and without successful treatment.

La imagen tiene un atributo ALT vacío; su nombre de archivo es PORTADA-ARTICULO-MARIO-GRANDE-1-1024x576.png

The NFX88 drug trial is already in an advanced clinical phase 2A in patients involving seven major hospitals in Spain. It is expected that this innovative and patented treatment will become the reference in the treatment of neuropathic pain associated with spinal cord injuries. NFX88 has reduced adverse effects and is much more effective than current reference treatments.

In the second quarter, Neurofix obtained authorization from the Spanish Medicines Agency (AEMPS) and the Spanish Medicines Ethics Committee (CEIM) to reduce the patient sample size, aiming at recruiting 48 patients compared to the 60 initially defined. This means a cost reduction and a significant acceleration of the end date of Phase 2A clinical program.

Given the consistent progress of the trial, the management team and the board of directors expect the results of the double-blind trial to be favorable, leading to a substantial improvement in the patient’s quality of life.

On the business side, Neurofix has been selected for the new Horizon Europe 2030 call, characterized by its high competitiveness, which would allow it to qualify for the exclusive EIC Accelerator funds for the next phase of clinical trials. After completing its first phase, Neurofix is in the process of executing a second, expected in September.  This milestone reflects the high potential of the company, aligned with the strategies set for Europe in its objectives of economic development, sustainability, and boosting the healthcare industry.

The company is part of BME Growth’s Pre-Market Environment with a view to making the leap to the alternative capital markets during the second quarter of 2022.

In relation to the business development strategy, the first contacts have been made in the business development area. Several multinational pharmaceutical companies have shown interest in receiving confidential information in order to evaluate the molecule as a candidate for a marketing license in different international markets. 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top